ACTRN12618001726246终止1 期
A Phase 1b, Multicentre, Open Label, Study of the Efficacy, Safety and Tolerability of R131 Ointment in Women with Cytological Abnormalities of the Uterine Cervix
适应症
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 13
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 22 Years 至 50 Years（—）
- 性别
- Female
入选标准
- •1.Provision of written informed consent prior to any study specific procedures;
- •2.Female participants aged 22-50 years inclusive at the time of screening visit;
- •3.Positive result for cervical high-risk HPV (types 16, 18 or other);
- •4.High-grade cytological abnormalities of the uterine cervix defined as HSIL/CIN 2 and above, confirmed by biopsy at Screening, or within 30 days prior to Screening visit,
- •low-grade cytological abnormalities of the uterine cervix defined as LSIL/ CIN1 as demonstrated by colposcopic biopsy collected at screening, or within 6 months prior to screening. Only collect biopsy sample if lesion is visible during colposcopic assessment. If no visible lesion, participant should be considered ineligible.
- •5.Transformation zone needs to be fully visible;
- •6.Generally, in good health with no clinically significant disease as determined by the investigator;
- •7.Regular menstrual cycle with an approximate 28-day cycle;
- •or women who are amenorrhoeic due to effective contraception (such as Mirena, Jadelle, or continuous COC)
- •8.Agree to abstain from activities such as vaginal douching or insertion of any vaginal products other than the study drug for at least 48 hours prior to enrolment and throughout the study. Tampons or menstrual cups may be used during the participant’s menstrual cycle only.
- •9.Women of childbearing potential (WOCBP) must use a highly effective form of birth control (confirmed by the Investigator). Rhythm methods will not be considered as highly effective methods of birth control. Highly effective forms of birth control include:
- •True sexual abstinence (defined as refraining from heterosexual intercourse for the duration of the study and a minimum of 30 days following the last dose of study drug);
- •Vasectomised partner (provided that the partner is the sole sexual partner of the female participant with childbearing potential and that the vasectomised partner has received medical assessment of the surgical success);
- •Oral or transdermal combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation;
- •Oral, injectable or implantable progestogen-only hormone contraception associated with inhibition of ovulation (Depo-Provera™, Implanon, Cerazette, Noriday (‘mini-pill’);
- •Any effective intrauterine device/levonorgestrel intrauterine system;
- •Female sterilisation by tubal occlusion;
- •Evra Patch™
- •WOCBP must agree to use a highly effective method of birth control, as defined above, from enrolment, and at least 14 days prior to Day 1, throughout the study duration and within 30 days after the last dose of IMP.
- •WOCBP are defined as women who are neither permanently sterilised (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), nor who are postmenopausal. Women will be considered post-menopausal if they have been amenorrhoeic for 12 months or more without an alternative biological or medical cause e.g. contraceptive method such as Mirena.
- •10.Male partners of female participants must agree to use condoms during sexual intercourse from the first dose of investigational product until 30 days after the participant’s last dose to avoid potential transfer of investigational product;
- •11.Able and willing to abstain from sexual intercourse for 6 hours after dosing;
- •12.Ability and willingness to attend the necessary visits to the clinical trial centre;
- •13. Ability to comprehend all study related
排除标准
- •1.Any significant disease or disorder (e.g. cardiovascular, pulmonary, gastrointestinal, hepatic, renal, neurological, musculoskeletal, endocrine, metabolic, malignant, psychiatric, major physical impairment) which, in the opinion of the investigator, may either put the participant at risk because of participation in the study, or may influence the results of the study, or the participant’s ability to participate in the study;
- •2.Any clinically significant abnormal findings in physical examination, vital signs, haematology, clinical chemistry, or urinalysis during screening and at baseline, which in the opinion of the investigator, may put the participant at risk because of her participation in the study, or may influence the results of the study, or the participant’s ability to complete entire duration of the study;
- •3.Pregnant, breastfeeding, or lactating women (WOCBP must have a negative serum pregnancy test at screening and a negative urine pregnancy test at the start of each treatment period [i.e. Day 1, Day 28, Day 56]);
- •4.Women who plan to become pregnant in the next 6 months;
- •5.History of genital herpes with >3 outbreaks per year, or active non-HPV vaginal infection;
- •6.Active pelvic infection (positive for gonorrhoea or chlamydial infection, positive test and symptoms for bacterial vaginosis, candida vaginitis or trichomonal vaginitis). Participants with positive results can be treated and re tested once during screening;
- •7.Positive bimanual exam consistent with pelvic inflammatory disease. Patients may be treated accordingly and re-screened;
- •8.Positive result for hepatitis B (surface antigen), hepatitis C antibody or human immunodeficiency virus;
- •9.Current or recent abnormal vaginal discharge and /or abnormal vaginal bleeding, within the 3 months prior to Day 1 as assessed by the investigator;
- •10.Had an abortion or miscarriage or taken the morning-after pill within the 3 months prior to enrolment;
- •11.Currently taking immunosuppressants, intra-vaginal preparations, or any prescription that in the opinion of the investigator could interfere with the interpretation of the results;
- •12.Previous exposure to lopinavir/ritonavir (within 3 months prior to screening), contraindication to the use of lopinavir/ritonavir or known allergy, hypersensitivity, or intolerance to any component of lopinavir/ritonavir vaginal ointment excipients;
- •13.Recent history (within 3 months prior to screening) of Stevens-Johnson syndrome, erythema multiforme, urticaria, angioedema, deep vein thrombosis, tinnitus, vertigo, blood glucose disorders, pancreatitis, haemophilia;
- •14.Receipt of any investigational product within 30 days or 5 half-lives prior to dosing;
- •15.Employees of the clinical study team or family members (first-degree relatives) of such individuals or anyone involved in the planning and/or conduct of the study. Clinical study team refers to employees directly involved in the study who have been delegated study-related tasks accordingly;
- •16.Participants who, in the opinion of the Investigator, do not understand the information and procedures of the study, or would not be compliant with them (in particular the study restrictions and risks involved).
研究者
相似试验
进行中（未招募）
1 期
A Phase I/II, Multicenter, Open-Label, Study of a Novel Bruton’s Tyrosine Kinase Inhibitor, Orelabrutinib, in Patients with B-Cell MalignanciesB-cell malignancies, including only patients with Grades 1-3a FL, MZL, MCL, and CLL/SLLMedDRA version: 20.0Level: HLGTClassification code 10025320Term: Lymphomas non-Hodgkin's B-cellSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2021-006475-42-PLInnoCare Pharma Inc.36
进行中（未招募）
1 期
A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background TherapyKidney Disease, GlomerulonephritisJPRN-jRCT2011220009ishizawa Atsushi16
招募中
1 期
M1774 in Combination with Cemiplimab in Participants with Non-Squamous NSCLC (DDRiver NSCLC 322)on-Squamous Non-Small Cell Lung CancerJPRN-jRCT2031230332Ishii Kyoko25
进行中（未招募）
不适用
A Phase I/II, Open Label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Tor Kinase Inhibitor AZD8055 Administered Orally to Patients with Advanced Solid TumoursEUCTR2008-002606-18-GBAstrazeneca AB100
进行中（未招募）
1 期
A Phase I/II, Open Label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Tor Kinase Inhibitor AZD8055 Administered Orally to Patients with Advanced Solid Tumours, Lymphomas and Endometrial CarcinomaEUCTR2008-002606-18-FRAstrazeneca AB100